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Background: Hepatoma-derived growth factor (HDGF) is a protein which is highly expressed in a variety of
tumours. HDGF has mitogenic, angiogenic, neurotrophic and antiapoptotic activity but the molecular mechanisms
by which it exerts these activities are largely unknown nor has its biological function in tumours been elucidated.
Mass spectrometry was performed to analyse the HDGFStrep-tag interactome. By Pull–down-experiments using
different protein and nucleic acid constructs the interaction of HDGF and nucleolin was investigated further.
Results: A number of HDGFStrep-tag copurifying proteins were identified which interact with RNA or are involved
in the cellular DNA repair machinery. The most abundant protein, however, copurifying with HDGF in this approach
was nucleolin. Therefore we focus on the characterization of the interaction of HDGF and nucleolin in this study.
We show that expression of a cytosolic variant of HDGF causes a redistribution of nucleolin into the cytoplasm.
Furthermore, formation of HDGF/nucleolin complexes depends on bcl-2 mRNA. Overexpression of full length bcl-2
mRNA increases the number of HDGF/nucleolin complexes whereas expression of only the bcl-2 coding sequence
abolishes interaction completely. Further examination reveals that the coding sequence of bcl-2 mRNA together
with either the 50 or 30 UTR is sufficient for formation of HDGF/nucleolin complexes. When bcl-2 coding sequence
within the full length cDNA is replaced by a sequence coding for secretory alkaline phosphatase complex formation
is not enhanced.
Conclusion: The results provide evidence for the existence of HDGF and nucleolin containing nucleoprotein
complexes which formation depends on the presence of specific mRNAs. The nature of these RNAs and other
components of the complexes should be investigated in future.
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HDGF (Hepatoma-derived growth factor) is the eponym-
ous member of a growth factor family comprising HDGF
and five additional proteins (HRP1-4, LEDGF). HDGF was
initially purified from serum-free supernatant of human
hepatoma cell line HuH-7 [1,2]. HDGF contains a charac-
teristic modular structure composed of an N-terminal re-
gion (amino acid residues 1–100; HATH region) conserved
among all members of the family and an acidic C-terminus
unique to HDGF [3,4]. Two nuclear localization signals,* Correspondence: franken@life-science-inkubator.de
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reproduction in any medium, provided the orone in the HATH region, and in the carboxy-terminal do-
main are prerequisites for the mainly nuclear localization of
HDGF [5,6]. However, in some cells HDGF appears also in
the cytoplasm [1,7].
In several studies it has been shown that recombinant
HDGF is implicated in cellular proliferation [8-11]. Fur-
thermore HDGF has been suggested to be neurotrophic
and involved in organ development and regeneration
[5,7,9,11-15]. However, no obvious biochemical or mor-
phological phenotype could be detected in a HDGF-
deficient mouse model [16].
Over the last decade, HDGF research focuses on its
possible role in tumour induction and/or tumour pro-
gression and metastasis. HDGF is highly expressed in a
wide variety of carcinomas and has been shown to be a
valid prognostic marker [17-27]. Beside its proliferativeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as antiapoptotic activity thereby making it an interesting
candidate for tumour therapy [28-31]. The latter activity
may be explained by a modulation of the expression of
members of the bcl-2 family of pro- and antiapoptotic
factors in human cancer cells by HDGF [28,32]. Besides
this, the molecular mechanisms of the antiapoptotic ac-
tivity of HDGF are poorly understood.
Here we describe the identification of proteins copuri-
fying with HDGFStrep-tag on Strep-TactinW-Macroprep
beads. By transfecting a DNA construct coding for an
HDGFStrep-tag fusion protein, we were able to purify
HDGFStrep-tag containing protein complexes and iden-
tified 98 possible interaction partners of HDGF. Beside
ribosomal proteins, heterogenous ribonucleoproteins, and
members of the cellular DNA-repair machinery we identi-
fied nucleolin as a possible HDGF interacting protein by
mass spectrometry and Western Blot. Similar to HDGF
nucleolin was reported to play an important role in tumour
biology by regulating proliferative, apoptotic and angio-
genic signalling pathways [33,34]. We therefore focused in
our study on a possible interaction of HDGF and nucleolin.
The presented experiments reveal that the interaction of
HDGFStrep-tag and nucleolin is RNA-dependent and
show that HDGF is able to regulate the cellular distribution
of nucleolin. Overexpression of bcl-2 mRNA enhances
complex formation of nucleolin and HDGFStrep-tag in
HeLa cells. Regarding our results we therefore propose a
RNA-containing nucleolin-HDGF protein complex pos-
sibly regulating the cellular amount of bcl-2 mRNA.
Methods
Cell culture
HEK 293 and HeLa cells were grown at 37°C under 95%
air/5% CO2 in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with GlutamaxW, 10% foetal calf
serum, and 1 mM penicillin/streptomycin. Cells were
splitted all 3 days and experiments were carried out be-
tween passages 5–15. HEK 293 cells were transfected
using calcium phosphate precipitation. Briefly, 2 × 106 cells
were seeded on 10 cm plates the day before transfection.
65 μl of a 2 M calcium chloride solution is mixed with
10 μg of DNA in 500 μl H2O. This solution is dropped
under stirration to 500 μl of Hepes buffered saline
pH 7.13. After 30 min of incubation at room temperature
the mixture is dropped to cells under mild rotation. HeLa
cells were transfected with Turbofect (Fermentas) follow-
ing the instruction of the manufacturer. All tissue culture
reagents were obtained from Invitrogen.
Plasmids
Sequence of murine HDGF was cloned into pCDNA3
vector (Clontech). To generate a Strep-tagW fusion pro-
tein, sequence of murine HDGF was inserted into aStreptagpCDNA3 vector with the Strep-tagW at the
c-terminus. Point mutation in the nuclear localization
signal 2 (NLS2) sequence (S155/170 to N155/170) of
murine HDGF was generated by PCR and inserted into
pCDNA3 vector.
DNAs coding for the different bcl-2 variants were gen-
erated by PCR using specific oligonucleotides given
below and were inserted into pCDNA3 vector.
Bcl-2 cds sense. gcaagcttctgggaaggatggcgca
Bcl-2 cds antisense. gcgaattctgttgacttcacttgtggccc
Bcl-2 ARE1 antisense. gcgaattcgatggtgatccggccaacaac
Bcl-2 30UTR antisense.
gcgcggccgcccaggatgtacagataacccccat
Bcl-2 50UTR sense. gcaagcttgtaagctctggagagtgctgaagat
Combinations of primers were Bcl-2 50UTR sense and
Bcl-2 30UTR antisense (for FL Bcl-2), Bcl-2 cds sense
and antisense (for cds), Bcl-2 cds sense with Bcl-2 ARE1
antisense (for ARE1), Bcl-2 cds sense with Bcl-2 30UTR
antisense (for 3UTR) and Bcl-2 50UTR sense with Bcl-2
cds antisense (for 5UTR).
Protein extraction
Whole cell lysates from transfected cells were prepared
by incubating cell pellets (10 × 106) in 250 μl ice-cold
buffer L containing 50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 7.5% Glycerol and 1 mM EDTA supplemented
with proteinase inhibitors (1 μg/ml pepstatin, 1 μg/ml
leupeptin, 2 mM pefabloc) for 30 min on ice. Suspen-
sions were sonicated three times for 10 s and centrifuged
at 13.000 × g for 30 min at 4°C. Supernatants were used
for analysis.
Protein purification
Lysates from transfection experiments were either
affinity-purified with Strep-TactinW-Macroprep beads or
spin columns (IBA). Briefly columns were equilibrated in
500 μl buffer W (100 mM Tris–HCl pH 8.0, 150 mM
NaCl, 1 mM EDTA) and centrifuged at 700 × g for
1 min. Lysates were applied onto the columns and cen-
trifuged two times at 700 × g for one minute. Columns
were washed four times with 100 μl buffer W and centri-
fuged each time at 13.000 × g for 30 s. Proteins were
eluted with buffer E (buffer W containing 2.5 mM Bio-
tin) and centrifuged for one minute at 700 × g followed
by thirty seconds at 13.000 × g. Beads were equilibrated
with buffer L and incubated with lysates for 2 h at 4°C.
Beads were washed four times with 500 μl buffer W and
centrifuged for 3 min at 3000 × g. Supernatants were
removed and beads were either directly digested with tryp-
sin for mass spectrometry analysis or eluted with 30 μl
buffer E. Eluate fractions were analyzed by Western blot
and mass spectrometry.
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anti-human HDGF antibody was immobilized on NHS
activated beads (1 μg/μl bead). 100 μl of these beads
were filled into a spin column (PIERCE) and washed
with 10 column volumes of PBS. HeLa whole cellular
extracts were prepared as described above and loaded
onto the HDGF affinity column. After washing the col-
umn with PBS containing 300 mM NaCl bound protein
was eluted with 50 mM citric acid pH 3. A column con-
taining rabbit IgG was used as a control. No elution of
HDGF or nucleolin was detected from this column.
Western blot analysis
Proteins were separated on a 10% SDS-PAGE gel and elec-
trotransferred to a PROTRAN nitrocellulose transfer
membrane (Whatman). Free binding sites were blocked
with 5% skimmed milk in Tris–HCl buffered saline (TBS)
pH 7.0 for one hour at room temperature. Primary anti-
bodies used were monoclonal anti nucleolin antibody (H-6,
Santa Cruz), peroxidase coupled Strep-TactinW (IBA) and
polyclonal anti HDGF antibody. Membranes were washed
three times for 10 minutes with TBS supplemented with
0.05% Tween20 (TBS/T). For detection peroxidase coupled
goat anti rabbit or goat anti mouse antibodies were used.
Membranes were washed again three times with TBS/T
and once with TBS before Western blotting chemilumines-
cent substrate (Pierce) was applied.
Immunocytochemical staining
Briefly, cells were transfected with either mouse HDGF
wild type or mouse HDGF-NLS2 mutant with Turbofect
reagent (Fermentas) following the instructions of the
manufacturer. After 48 hours, HeLa cells were fixed by in-
cubation in ice-cold methanol for 10 min on ice. Coverslips
were washed three times with TBS and blocked with 3%
bovine serum albumin (BSA) in TBS for 30 min at room
temperature. Antigens were detected by incubation with
polyclonal rabbit anti HDGF antibody (1:200) and mono-
clonal mouse anti nucleolin antibody (1:800, Santa Cruz) in
1% BSA in TBS for one hour at room temperature. Bound
antibodies were visualized using Cy3-conjugated goat anti
rabbit (1:500) or Alexa 488-conjugated goat anti mouse
(1:400) antibodies (Dianova). Cells were counterstained
with 406-diamidine-2-phenylidole-dihydrochloride (DAPI).
Coverslips were mounted in Mowiol and analyzed by epi-
fluorescence microscopy on an Axiovert 100 M instrument
(Zeiss, Jena, Germany).
RNAse digestion
Cell extracts were incubated with RNAse A (Fermentas)
prior to protein purification. Briefly, cell lysates were
treated with 25 μg/ml RNAse A at 4°C over night under
mild rotation. Protein purification was carried out as
described previously.RT-PCR
Cells were transfected as described and 48 h after transfec-
tion RNA was isolated using 8 ml TRIzol™ (Invitrogen)
according to manufacturer’s instruction. Five hundred
nanogram RNA was used for cDNA synthesis using Oligo
dT-primer and the ReverdAid Kit (Qiagen) as recommend
by the supplier. One microliter of cDNA was used for
PCR. Primer sequences for 50UTR of bcl-2 were 50GC
AAGCTTGTAAGCTCTGGAGAGTGCTGAAGAT30
(sense) and 50GCGAATTCCCTTCCCAGAGGAAAA
GC30 (antisense) and for GAPDH were 50GATGACATC
AAGAAGGTGGTGA30 and 50CTGTAGCCAAATTCGT
TGTCAT30. The PCR program consisted of initial de-
naturation at 95°C for 30 s, annealing at 54°C for 30 s and
extension at 72°C for 1 min for 25 cycles in case of the
bcl-2 50UTR and 20 cycles for GAPDH. The specificity of
all PCR reactions was tested by parallel reactions using
water instead of cDNA (not shown). The PCR products
were subjected to agarose gel electrophoresis and visua-
lized by ethidium bromide staining.
Mass spectrometry
For analysis peptides generated by tryptic digest of
Strep-TactinW-Macroprep beads were separated using an
Ultimate 3000 RSLCnano system (Dionex-LC Packings,
Idstein, Germany). Samples were loaded onto a trapping
column (Acclaim PepMap Nanotrap, 75 μm× 20 mm)
by the loading pump of the system operating at 5 μL/
min, and 0.1% trifluoroacetic acid in water was used as
mobile phase. After 6 min, valve was switched and the
sample was eluted onto the analytical separation column
(Acclaim PepMap RSLC, 75 μm× 150 mm), using a flow
rate of 300 nL/min. The mobile phases used were H2O/
0.1% formic acid (v/v) for buffer A and 80% ACN/0.1%
formic acid (v/v) for buffer B. Peptides were resolved by
gradient elution using a gradient of 2 − 55% buffer B
over 30 min, followed by a gradient of 50 − 90% buffer B
over 2 min. After 5 min at 90% B the gradient returned
to 5% buffer B preparing for the next run. Column efflu-
ent was monitored using a 3 nL UV flow cell (214 nm).
Mass spectrometric analysis was done via ESI-MS/MS
using a LTQ-Orbitrap Velos mass spectrometer (Thermo
Fisher, Bremen, Germany) equipped with a nano-electro-
spray ion source. The mass spectrometer was operated in
the data dependent mode. Survey MS scans were
acquired in the orbitrap with the resolution set to 30.000.
Up to 15 most intense ions per scan were fragmented
and analyzed in the linear ion trap.
The raw files were processed using Proteome Discoverer
software version 1.3 (Thermo). The peak list files were
searched against Swissprot human database by the MAS-
COT search engine. The initial parent and fragment ion
maximum mass deviation were set to 10 ppm and 0.8 Da,
respectively. The search included variable modifications of
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cysteine. The false discovery rate was set to 0.01.
Gene ontology data were added by use of the AmiGO
web tool ([35] http://amigo.geneontology.org).
For peptide analysis after SDS-PAGE proteins of
interest were cut from Coomassie stained gels and pro-
cessed using a Trypsin Profile IGD Kit (Sigma-Aldrich,
USA) following the manufacturer’s instructions. For
analysis eluted peptides were separated using an Ul-
timate 3000 LC system (Dionex-LC Packings, Idstein,
Germany). Samples were loaded onto a monolithic trap-
ping column (PepSwift, 200 μm× 5 mm) by the loading
pump of the system operating at 10 μL/min, and 0.1%
Heptafluorobutyric acid in water was used as mobile
phase. After 5 min, valve was switched and the sample
was eluted onto the analytical separation column (PepS-
wift monolithic capillary column, 200 μm× 50 mm),
using a flow rate of 500 nL/min. The mobile phases
used were H2O/0.1% Formic acid (v/v) for buffer A and
100% Acetonitril (ACN)/0.1% Formic acid (v/v) for buf-
fer B. Peptides were resolved by gradient elution using a
gradient of 5 − 50% buffer B over 20 min, followed by a
gradient of 50 − 90% buffer B over 1 min. After 5 min at
90% B the gradient returned to 5% buffer B preparing
for the next run. Column effluent was monitored using
a 3 nL UV flow cell (214 nm).
Mass spectrometric analysis was done via online ESI-
MS/MS using an HCTUltra ion trap mass spectrometer
(Bruker Daltonics, Bremen, Germany). All measurements
were carried out in positive ion mode. MS-spectra were
acquired in standard-enhanced mode between 300 to
2000 m/z at a rate of 8,100 m/z/sec. Fragmentation of pep-
tides from MS-spectra using CID was done in Auto-MS2
mode, selecting precursor ions according to the following
parameters: number of precursor ions = 5, minimal ion in-
tensity = 10,000, ion excluded after 2 spectra, exclusion re-
lease after 1 min. MS2 data acquisition was done in
ultrascan mode with a scan range of 50–3000 m/z at a scan
speed of 26,000 m/z/sec.
Raw MS data for each LC run were processed using
DataAnalysisTM version 4.0. The spectrum was screened
for compounds using the software’s AutoMS/MS search
feature applying following parameters: intensity threshold
= 10,000; max number of compounds = 500; retention
time = 0.4. Identified compounds were subsequently de-
convoluted and exported for protein database comparison
with BioToolsTM version 3.1. In BioToolsTM the ex-
ported compounds were run against an in-house Swis-
sProt v51.6 database using the Mascot 2.2.02 algorithm.
The searches were carried out using the following para-
meters: enzyme = trypsin; missed cleavages = 1; taxonomy
= All entries; variable modifications = oxidation (M) and
carbamidomethylation (C); peptide tolerance = 300 ppm;
MS/MS tolerance = 1.1 Da; significance threshold p = 0.05.Results
Affinity purification and identification of components of
HDGF containing protein complexes
To learn more about how HDGF might exert its bio-
logical effects we decided to identify interaction partners
of the protein after overexpression in HEK293 cells by
taking advantage of the stringent purification scheme of
the Strep-tag/Strep-TactinW system [36,37]. Protein
lysates from HEK cells expressing HDGFStrep-tag or as
a control GFP-StrepTag fusion proteins were applied to
a Strep-TactinW MacroPrep matrix. After washing, beads
were incubated with trypsin and released tryptic peptides
were analysed by ESI-MS/MS (Flow chart of the experi-
ment see Figure 1A). To control reproducibility this ex-
periment was performed four times each for HDGF and
GFP, starting with the transfection of the DNA con-
structs coding for the Strep-tagged proteins into
HEK293 cells. Results were searched against Swissprot
human protein database using Mascot search engine and
all proteins identified by two or more peptides and with
a sum PSM (peptide spectrum matches) of higher then
nine were included into a result list. This list contained
112 and 85 interacting proteins for HDGFStrep-Tag and
GFPStrep-tag lysates, respectively, of which 14 were
identified in both samples (Figure 1B; complete lists in
Additional files 1, 2 and 3). Subtraction of the overlap-
ping proteins resulted in a list of 98 proteins only found
in the HDGFStrep-Tag interactome. GO molecular
function analysis of these proteins shows that many of
them have binding functions (84.7%), including protein
binding (56.1%) and nucleic acid binding, especially RNA
binding (63.3%) (Figure 1C and Additional file 4). Besides
HDGF, the highest score and the highest number of PSMs
were obtained for nucleolin (Additional file 1), a protein
known to be involved in proliferation, apoptosis and
neoangiogenesis similar to what was reported for HDGF.
Due to this surprising overlap with HDGF function we fo-
cused on nucleolin in our further analysis.
First of all we confirmed copurification of nucleolin
with HDGF by an independent SDS-PAGE gel based
identification strategy. Therefore, HDGFStrep-tag copur-
ifying proteins where not digested directly on the beads
but were eluted with biotin, separated by SDS-PAGE,
and the most abundant coeluting proteins were stained
by Coomassie Brilliant Blue (Figure 2A). Besides a strong
signal corresponding to HDGFStrep-tag additional pro-
teins of higher molecular weight could be detected spe-
cifically copurifying in the presence of HDGFStrep-tag
but not in the eluate prepared from cells transfected with
a control construct. Peptides released from gel pieces by
tryptic digest were analysed by nanoLC-ESI-Iontrap mass
spectrometry. MASCOT database searches of the peptide
sequences revealed highly significant protein identifica-
















Figure 1 Mass spectrometry analysis of purified HDGF protein complexes. HDGF interaction partners were isolated using Strep-TactinW-MacroPrep
matrices as affinity resin to purify HDGFStrep-tag proteins. Trapped proteins were digested by trypsin and peptides analyzed by ESI-MS/MS. (A) Flow
chart of the experiment. (B) Venn diagramm showing the overlap between HDGFStrep-tag and GFPStrep-tag interactome. (C) Pie chart of molecular
functions of HDGFStrep-tag interaction partners (see also Additional file 4).
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quence coverage of 22%, fourteen peptides for Ku86 (26%
sequence coverage), fifteen peptides for PARP1 (18% se-
quence coverage) and twenty peptides for DNA-Pkcs (8%
sequence coverage) were identified (see Additional file 5).
To confirm our mass spectrometry results we performedWestern blotting on the HDGFStrep-tag eluate fractions
using a specific nucleolin antibody. Results in figure 2B
demonstrate the specific coelution of nucleolin from the
HDGFStrep-tag resin using transfected HEK293 cells. In
addition copurification of Ku86 could also be proofed by




















































Figure 2 Verification of nucleolin copurification with HDGF. (A) Analysis of most abundant HDGFStrep-tag copurifying proteins by Coomassie
stained SDS-PAGE. Proteins purified via Strep-TactinW-MacroPrep matrices after transfection of cells with HDGFStrep-tag or untagged HDGF
(Mock) were separated using SDS-PAGE and visualized by Coomassie staining. Visible proteins specific for HDGFStrep-tag sample correspond to
Ku86 (86 kDa), nucleolin (110 kDa), PARP-1 (113 kDa) and the catalytic subunit of DNA-PK (460 kDa). (B) To confirm mass spectrometric results,
lysates of HEK293 cells expressing HDGFStrep-tag fusion proteins and their eluate fractions from HDGFStrep-tag purification were examined by
Western blot with a specific nucleolin antibody. Nucleolin is only present in eluates from cells expressing HDGFStrep-tag fusion proteins. (C) To
investigate whether endogenous HDGF also interacts with nucleolin a cellular extract of untransfected HeLa cells was loaded onto a human
HDGF antibody column. Non-specific proteins were washed out with 300 mM NaCl. Specifically binding proteins were eluted with 50 mM citric
acid pH 3. Western blot analysis with a monoclonal anti nucleolin antibody confirmed copurification of nucleolin with endogenous HDGF.
Bremer et al. BMC Biochemistry 2013, 14:2 Page 6 of 13
http://www.biomedcentral.com/1471-2091/14/2HDGF is part of a RNA-dependent nucleolin containing
complex and influences cellular distribution of nucleolin
Influence of nucleolin on cellular mRNA content in
HeLa cells has been studied extensively in a recent study
[38]. Therefore, extracts from untransfected HeLa cells
were passed over a human HDGF antibody column to
investigate whether the nucleolin-HDGF complex for-
mation can also be observed with endogenous HDGF.
Unspecifically bound proteins were removed by washing
with high salt containing buffer. Proteins bound to the
column via the HDGF antibody were eluted with 50 mM
citric acid pH 3. Eluted proteins were separated by SDS-
PAGE, transferred onto nitrocellulose membrane and
subjected to Western blot analysis. Immunoblotting with
a monoclonal nucleolin antibody confirmed specific
binding of nucleolin to the HDGF antibody column(Figure 2C). Thus, the interaction of HDGF with nucleo-
lin is not a specific feature of the HDGFStrep-tag fusion
proteins but occurs also with unfused endogeneous pro-
tein. Interestingly, for both strategies described here only
the full length nucleolin showed efficient copurification
together with HDGF whereas smaller forms detected by
the specific antibody against nucleolin did not purified
together with HDGFStrep-tag as well as endogenous
HDGF. This observation points to the specificity of the
purification protocol.
HDGF is predominantly a nuclear protein with low ex-
pression in the cytoplasm. Recent data, however, suggest
a cytoplasmic localization in certain tumours. Nucleolin
is primarily a nucleolar protein with the ability to shuttle
between nucleus, cytoplasm and cell surface. To investi-
gate whether cellular localization of nucleolin can be
Bremer et al. BMC Biochemistry 2013, 14:2 Page 7 of 13
http://www.biomedcentral.com/1471-2091/14/2manipulated by HDGF, HeLa cells were transfected with
an expression vector encoding for a murine HDGF cDNA
with a mutation in the NLS2 (Nuclear Localization Signal
2) sequence which has been shown before to cause a pre-
dominant cytoplasmic localization of HDGF (HDGF-
NLS2). Cells transfected with the HDGF-NLS2 showed
strong nucleolin expression in the cytoplasm (Figure 3A,
panel d) whereas in cells with wild type HDGF nucleolin
was retained mainly in the nucleus (Figure 3A, panel c).
To quantify this effect, we counted cells (n = 100) positive
for HDGF staining and analysed these cells with regard to
their localisation of nucleolin. We distinguished nuclear
and cytoplasmic localization. 67% of cells transfected with
HDGF-NLS2 showed translocation of nucleolin from nu-
cleus to cytoplasm. In comparison, only 7% of wild type
HDGF transfected cells showed this effect (Figure 3B).
















Figure 3 HDGF changes intracellular distribution of nucleolin. (A) To e
transfected with either wild type HDGF or a HDGF-NLS2 mutant expression
wild type HDGF (HDGFwt) show predominant nuclear localization of HDGF
In contrast, induction of cytoplasmic expression of HDGF-NLS2 leads to a s
as nucleolin (green, Figure 3B panel d). Cells were counterstained with DAP
localisation of nucleolin was analysed. 67% of HDGF-NLS2 transfected cells
of wild type transfected cells. *p < 0.001. (C) Protein lysates from HDGFStre
(25 μg/ml) over night at 4°C followed by affinity purification via Strep-Tacti
subjected to Western blot analysis using a specific nucleolin antibody (upp
HDGFStrep-tag (lower panel). In samples treated with RNAse A a completeleads to substantial cytoplasmic nucleolin localization.
This observation is strong evidence of functionally rele-
vant in vivo interaction of HDGF and nucleolin.
HDGF was shown to exhibit binding activity upon
ribosomal RNAs [39]. In accordance to this we observed
copurification of RNA from HeLa as well as HEK 293
cells during purification of HDGFStrep-tag. Together
with 2 μg of protein an average of 15 μg RNA could be
eluted from HDGFStrep-tag MacroPrep beads. In com-
parison unspecific RNA binding of beads not loaded
with protein was less than 1 μg (data not shown).
Nucleolin was reported to interact with other proteins in
a RNA-dependent manner [40]. Therefore we investi-
gated whether HDGFStrep-tag-nucleolin interaction
depends on the presence of RNA. Therefore, cell lysates
of HeLa cells expressing HDGFStrep-tag fusion proteins





































xamine HDGF/nucleolin complex formation in HeLa cells, cells were
vector and fixed after 48 hours with methanol. Cells transfected with
(red, Figure 3B panel a) as well as nucleolin (green, Figure 3B panel c).
ignificant increase of cytoplasmic HDGF (red, Figure 3B panel b) as well
I (blue). (B) HDGF positive cells were counted (n = 100) and
show cytoplasmic localisation of nucleolin in comparison to only 7%
p-tag expressing HeLa cells were incubated with or without RNAse A
nW-MacroPrep spin columns. Proteins from eluate fractions were
er panel) or with peroxidase coupled Strep-TactinW to detect
loss of interaction can be observed.
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tein complexes. This treatment completely abolished the
interaction of HDGFStrep-tag and nucleolin as detected
by Western blotting against nucleolin (Figure 3C).
HDGF-nucleolin complex formation is mediated by bcl-2
full length mRNA
To investigate whether HDGF-nucleolin copurification
occurs because of HDGFs general RNA binding activity or
whether it depends on the presence of certain mRNAs we
screened the literature for functional overlaps in HDGF
and nucleolin activity. The latter is known to regulate cel-
lular bcl-2 protein amount by binding to and stabilizing its
mRNA. Interestingly, HDGF was also reported to manipu-
late cellular bcl-2 content [28,40].
To examine whether bcl-2 mRNA might be involved in
the observed complex formation we took advantage of
Paclitaxel, a substance which was reported to destabilize
















Figure 4 HDGF and nucleolin complex formation depends on bcl-2 fu
mRNA in HDGF-nucleolin complex formation cells were treated with Paclita
described above. Incubation with the bcl-2 mRNA destabilizing agent Pacli
Different deletion constructs of bcl-2 mRNA were generated and cotransfe
copurification of nucleolin. The full-length bcl-2 mRNA (FL Bcl-2) had a pos
on the amount of coprecipitated nucleolin. Interestingly, addition of 400 b
was already sufficient to rescue the negative effect on the amount of prec
rescuing effect on the interaction.depends on the presence of bcl-2 mRNA Paclitaxel treat-
ment should reduce the amount of nucleolin copurified
with HDGFStrep-tag fusion protein. Indeed, addition of
500 μM Paclitaxel to the cell culture medium of HeLa
cells led to a significant decrease of nucleolin in the
HDGFStrep-tag eluate fractions (Figure 4A).
To proof the role of bcl-2 mRNA in HDGFStrep-tag-
nucleolin complex formation HeLa cells were transfected
with a vector encoding different parts of bcl-2 mRNA and
the HDGFStrep-tag fusion protein (Figure 4B). All con-
structs led to a similar degree of bcl-2 protein expression
in transfected cells (Figure 4C lower panel). After purifi-
cation of the HDGFStrep-tag fusion protein via affinity
chromatography nucleolin was detected in the eluate
fractions. Figure 4C shows that expression of a full length
version of bcl-2 mRNA (FL Bcl-2) leads to an increased
amount of nucleolin in the eluate fractions. This indi-
cates that bcl-2- mRNA causes an enhanced interaction






























ll length mRNA. (A) To investigate a possible involvement of bcl-2
xel and protein lysates were examined for nucleolin copurification as
taxel led to a significant decrease of nucleolin copurification. (B + C)
cted together with HDGFStrep-tag to investigate their influence on the
itive whereas the coding sequence of bcl-2 (cds) had a negative effect
p of the 30UTR (ARE1) containing a known nucleolin binding motive
ipitated nucleolin. Furthermore, beside the 30UTR also the 50UTR had a
Bremer et al. BMC Biochemistry 2013, 14:2 Page 9 of 13
http://www.biomedcentral.com/1471-2091/14/2Nucleolin was reported to bind to the UTR’s of bcl-2
mRNA [40]. If the interaction of HDGFStrep-tag and
nucleolin depends on nucleolin binding to bcl-2 mRNA
one would expect that the coding sequence of bcl-2
alone will not increase the amount of nucleolin copurify-
ing with HDGFStrep-tag. Surprisingly, transfection of the
corresponding construct (cds) not only failed increasing
nucleolin copurification but inhibited the complex forma-
tion of HDGF and nucleolin completely (Figure 4C). To
localize bcl-2-mRNA regions responsible for HDGFStrep-
tag nucleolin interaction in more detail we also transfected
several vectors expressing different sections of the bcl-
2-mRNA (Figure 4B). In contrast to the cds alone con-
structs containing one or both UTRs were able to restore
the activity of the bcl-2 mRNA to increase HDGFStrep-
tag nucleolin interaction. Even addition of the ARE1 that
was reported to be the minimal motive for nucleolin bind-
ing to the bcl-2 mRNA was sufficient to restore the




















Figure 5 Cds of bcl-2 mRNA is necessary for HDGF and nucleolin com
sequence of bcl-2 (cds) it was replaced by the cds of secreted alkaline pho
bcl-2 UTRs in the cells as detected by RT-PCR. (C) Replacement of the cds o
of coprecipitated nucleolin.To examine whether the UTRs are not only necessary
but sufficient for this effect, we exchanged the cds of
bcl-2 in its full length construct (FL Bcl-2) for the cds of
the secreted alkaline phosphatase (FL SEAP; Figure 5A).
RT-PCR demonstrates the increased amount of the bcl-2
UTRs after transfection of constructs coding for the bcl-
2 full length mRNA as well as the bcl-2/SEAP chimera
in contrast to the cds alone (Figure 5B). Interestingly,
only the full length bcl-2 construct was able to increase
copurification of nucleolin demonstrating an important
role of the bcl-2 cds in HDGFStrep-tag nucleolin com-
plex formation in addition to its UTRs (Figure 5C).
Discussion
In multiple studies it has been shown that elevated levels
of HDGF in different types of tumours correlate with
metastatic potential, increased malignancy and thus, a
unfavourable prognosis for patients [17-22,24,25,42].





plex formation. (A) To investigate a possible role of the coding
sphatase (SEAP). (B) Both constructs led to a significant increase in
f bcl-2 against the cds of SEAP was not able to increase the amount
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ranging from proliferation to angiogenesis and cellular
survival [28,29,31,32,43,44]. Regarding the latter, HDGF
has been reported to exert antiapoptotic activity via the
regulation of members of the bcl-2 protein family. De-
pending on different cell types upregulation of bcl-2
(antiapoptotic) or downregulation of bad (proapoptotic)
was reported. However, whether HDGF achieves these
modulations via transcriptional control mechanisms
like reported for the SET and MYND domain containing
1 gene [45] or on a posttranscriptional level is com-
pletely unknown.
In this report, we investigated the HDGF interactom.
Most of the proteins identified here have functions in
RNA biogenesis and processing. Furthermore, we identi-
fied members of DNA repair pathways XRCC6/Ku70,
XRCC5/Ku86, PARP1 and DNA-PKcs among the most
prominent HDGF interaction partners. PARP-1 was
shown before to form a complex with both DNA-PKcs
and Ku70/Ku86 [46,47]. This complex plays an import-
ant role in non-homologous end joining a special form
of DNA repair [48]. Lepourcelet and coworkers reported
the correlation of HDGF reexpression with mismatch re-
pair proficient colon carcinoma in contrast to carcin-
omas deficient for this type of DNA repair suggesting an
involvement of HDGF in this kind of biological process
[49]. Furthermore, a more global approach on HDGF
interactions also found different members of DNA repair
pathways as possible interaction partners of HDGF [39].
The biological relevance of this finding is subject of fur-
ther investigation but the identification of all three pro-
teins underlines the specificity of our approach.
Besides the members of DNA repair pathways nucleo-
lin copurified with HDGF. Multiple functions have been
assigned to nucleolin a RNA-binding phosphoprotein of
the nucleolus. Besides its function in ribosomal biogen-
esis nucleolin is associated with many processes dysfunc-
tional in tumour cells [34,50]. These properties are in
line with probable HDGF functions. Most interestingly,
nucleolin has been shown to be a key regulator of bcl-2
via binding and stabilizing its mRNA [40]. Therefore, to
investigate possible biological relevance of our results we
focused on the HDGF-nucleolin interaction. First of all
using an antibody based affinity chromatography approach
we demonstrated the existence of an HDGF-nucleolin
containing complex also for endogenous HDGF. This is
important because all other proteomic studies to date only
reported interactions after overexpression of HDGF.
Nucleolin is a protein with predominant localization
in the nucleus but is also able to translocate to the cyto-
plasm similar to what was reported for HDGF. Of inter-
est, as shown in Figure 3, HDGF is able to regulate the
cellular localisation of nucleolin in HeLa cells. This find-
ing again underlines the in vivo relevance of the HDGF-nucleolin interaction. Previous data suggest that the
phosphorylation state of nucleolin is important for the
efficiency of nucleolin shuttling [51]. Whether phosphor-
ylation/dephosphorylation signalling or other mechan-
isms are involved in HDGF-nucleolin shuttling has to be
revealed in further studies.
Nucleolin has RNA binding activity and many interac-
tions of nucleolin occur in the presence of RNA. Binding
to ribosomal RNAs has also been recently demonstrated
for HDGF [39]. Not surprisingly the observed copurifica-
tion of nucleolin with HDGFStrep-tag is also dependent
on RNA. Here we show that specifically bcl-2 mRNA is
able to mediate HDGF-nucleolin complex formation.
Regulation of bcl-2 on mRNA as well as protein level has
attracted increasing attention over the last years and is
frequently an obstacle on cancer treatment [52-54]. Bcl-2
mRNA stabilization and regulation of translation effi-
ciency is regulated by nucleolin via binding to AU-rich
elements (ARE) in the 30untranslated region (30UTR)
[55,56]. Consistent with this we show that the presence
of these regions is a prerequisite for the bcl-2 mRNA
induced HDGF-nucleolin complex formation.
Formation of the HDGF-nucleolin complex depends
on the presence of either the 30 or 50 UTR in combin-
ation with the coding sequence, respectively. In contrast,
the coding sequence alone or its replacement by an un-
related coding sequence does not propagate complex
formation. This clearly shows that the combination of
UTRs and bcl-2 coding sequence is essential for HDGF-
nucleolin interaction. HDGF has been shown to bind
RNA rather unspecifically [39]. A model compatible with
the bcl-2 mRNA dependent formation of the HDGF/
nucleolin complex would be that HDGF binds the cod-
ing sequence rather unspecifically and that nucleolin is
incorporated via regions of the 3 and 50 UTR.
Besides its already known function as a transcriptional
repressor the results described here point to a possible
role of HDGF in RNA transport, stability and/or transla-
tional control. Furthermore nucleolin was shown to
regulate transport of mRNA as a member of ribonucleo-
protein complexes [57] and translation for example of
p53 together with ribosomal protein L26 [58]. Future
approaches should therefore target possible roles of
HDGF in RNA transport and translational control.
It is also not known whether there is a direct inter-
action between HDGF and nucleolin. This finding
would be interesting regarding a possible interaction of
HDGF and nucleolin at the cell surface. Nucleolin was
reported to function as cell surface receptor for mole-
cules like midkine or pleiotrophin [59-61]. Interestingly,
as reported for HDGF nucleolin can also bind to certain
glycosaminoglycans [3,8,42,62,63] and heparin binding
motifs of potential ligands can function as binding
motifs for nucleolin [64]. Similar to ribonucleic acids
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iety of protein-protein interactions. Nucleolin therefore
could possibly serve as the up to now unknown cell
surface receptor for HDGF in a GAG-dependent way
explaining at least some of its proliferative as well
angiogenic properties as an extracellular factor during
tumour formation.
Conclusions
HDGF has been reported to be overexpressed in a wide
variety of tumours and its expression correlates with an
unfavourable prognosis for cancer patients. But how
HDGF exactly contributes to tumourigenesis is not
known up to now. Interestingly, in this study we dem-
onstrate that nucleolin, a protein known to be involved
in a set of processes relevant during tumourigenesis,
can participate in these complexes and that the mRNA
of bcl-2, a known regulator of apoptosis, contributes to
their composition. The results presented here give evi-
dence that beside its activity as a transcriptional repres-
sor intracellular HDGF might exerts some of its cellular
functions by posttranscriptional regulation of RNAs as
a member of nucleoprotein complexes. These findings
therefore contribute to the understanding of a possible
role of HDGF during tumour onset and progression and
are the base for a new set of biochemical and cell bio-
logical experiments addressing HDGF biology.
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Additional file 1: HDGF interactome. Four biological replicates each
were analyzed for HDGFStrep-tag or GFPStrep-tag copurifying proteins by
ESI-MS/MS. Proteome discoverer software were used to produce
multiconsensus lists of the four HDGF and the four GFP replicates. Lists
were filtered for proteins with at least 2 peptide hits and at least 10
peptide spectrum matches (PSM). Afterwards proteins present in both
lists were subtracted to receive the HDGF interactome.
Additional file 2: Multiconsensus list of four HDGF measurements.
Four biological replicates each were analyzed for HDGFStrep-tag
copurifying proteins by ESI-MS/MS. Proteome discoverer software were
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list was filtered for proteins with at least 2 peptide hits and at least 10
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Four biological replicates each were analyzed for GFPStrep-tag
copurifying proteins by ESI-MS/MS. Proteome discoverer software were
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was filtered for proteins with at least 2 peptide hits and at least 10
peptide spectrum matches (PSM).
Additional file 4: Gene ontology annotations of the HDGF
interactome. Proteins present in the HDGF interactome (see Additional
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Additional file 5: Peptide hits of proteins processed by SDS-PAGE
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identified proteins were listed together with measured and calculated
peptide masses.Additional file 6: Western blot against Ku86/XRCC5. To confirm mass
spectrometric results, lysates of HEK293 cells expressing HDGFStrep-tag
fusion proteins and their eluate fractions from HDGFStrep-tag purification
were examined by Western blot with a specific Ku86 antibody. Ku86 is
only present in eluates from cells expressing HDGFStrep-tag fusion
proteins.
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